data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Enlivex Therapeutics
(NASDAQ:ENLV)
4.9177
0.2777[5.98%]
Last update: 2:49PM
15 minutes delayed
Day High/Low4.41 - 4.97
52 Week High/Low3.65 - 13.95
Open / Close4.51 / -
Float / Outstanding17.2M / 18.4M
Vol / Avg.34.3K / 81.2K
Mkt Cap90.4M
P/E-
50d Avg. Price4.81
Div / Yield-
Payout Ratio-
EPS-0.45
Total Float17.2M

Enlivex Therapeutics (NASDAQ:ENLV), Quotes and News Summary

Enlivex Therapeutics (NASDAQ: ENLV)

Day High/Low4.41 - 4.97
52 Week High/Low3.65 - 13.95
Open / Close4.51 / -
Float / Outstanding17.2M / 18.4M
Vol / Avg.34.3K / 81.2K
Mkt Cap90.4M
P/E-
50d Avg. Price4.81
Div / Yield-
Payout Ratio-
EPS-0.45
Total Float17.2M
Benzinga - 4 days ago
Benzinga - Sponsored
Benzinga - Sponsored
Benzinga - Jun 6, 2022, 8:02AM
Benzinga - May 25, 2022, 8:02AM
Benzinga - May 5, 2022, 8:38AM
Benzinga - May 3, 2022, 7:21AM
Benzinga - May 2, 2022, 8:17AM
Benzinga - May 2, 2022, 6:15AM
Benzinga - Apr 29, 2022, 8:43AM
Benzinga - Apr 29, 2022, 8:17AM
Benzinga - Apr 19, 2022, 7:26AM
Benzinga - Mar 8, 2022, 8:04AM
Benzinga - Dec 13, 2021, 8:03AM
Benzinga - Dec 7, 2021, 8:01AM
Benzinga - Dec 6, 2021, 8:15AM
Benzinga - Nov 22, 2021, 8:18AM
Benzinga - Nov 10, 2021, 8:07AM
Benzinga - Nov 4, 2021, 8:18AM
Benzinga - Oct 5, 2021, 8:17AM
Benzinga - Oct 4, 2021, 8:05AM
Benzinga - Sep 22, 2021, 6:04AM
Benzinga - Aug 16, 2021, 9:43AM
load more
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-19
REV
Q1 2022Est.ActualSurprise
EPS
(EXPECTED)2022-07-08
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Enlivex Therapeutics Questions & Answers

Q
How do I buy Enlivex Therapeutics (ENLV) stock?
A

You can purchase shares of Enlivex Therapeutics (NASDAQ: ENLV) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Enlivex Therapeutics's (ENLV) competitors?
A

There are no as such competitors for Enlivex Therapeutics.

Q
What is the target price for Enlivex Therapeutics (ENLV) stock?
A

The latest price target for Enlivex Therapeutics (NASDAQ: ENLV) was reported by HC Wainwright & Co. on Monday, May 2, 2022. The analyst firm set a price target for 15.00 expecting ENLV to rise to within 12 months (a possible 205.02% upside). 1 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Enlivex Therapeutics (ENLV)?
A

The stock price for Enlivex Therapeutics (NASDAQ: ENLV) is $4.9177 last updated Today at June 27, 2022, 6:49 PM UTC.

Q
Does Enlivex Therapeutics (ENLV) pay a dividend?
A

There are no upcoming dividends for Enlivex Therapeutics.

Q
When is Enlivex Therapeutics (NASDAQ:ENLV) reporting earnings?
A

Enlivex Therapeutics’s Q2 earnings are confirmed for Friday, August 19, 2022.

Q
Is Enlivex Therapeutics (ENLV) going to split?
A

There is no upcoming split for Enlivex Therapeutics.

Q
What sector and industry does Enlivex Therapeutics (ENLV) operate in?
A

Enlivex Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.